Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-986158 is a highly effective BET inhibitor, demonstrating IC50 values of 6.6 nM in NCI-H211 small cell lung cancer (SCLC) cells and 5 nM in MDA-MB231 triple negative breast cancer (TNBC) cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 79.00 | |
5 mg | In stock | $ 272.00 | |
10 mg | In stock | $ 490.00 | |
25 mg | In stock | $ 785.00 | |
50 mg | In stock | $ 1,080.00 | |
100 mg | In stock | $ 1,460.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 297.00 |
Description | BMS-986158 is a highly effective BET inhibitor, demonstrating IC50 values of 6.6 nM in NCI-H211 small cell lung cancer (SCLC) cells and 5 nM in MDA-MB231 triple negative breast cancer (TNBC) cells. |
Targets&IC50 | BET:5 nM (in MDA-MB231 TNBC) cells), BET:6.6 nM(in NCI-H211 SCLC cells) |
In vitro | BMS-986158 acts as an inhibitor targeting the bromodomain (BRD) and extra-terminal domain (BET) protein family, offering potential for cancer treatment. When administered, BMS-986158 attaches to the BRD's acetyl-lysine binding site on BET proteins, blocking their interaction with acetylated histones. This interruption hampers chromatin remodeling and curbs the expression of genes that promote growth, thereby inhibiting tumor cell proliferation[2]. |
Molecular Weight | 495.62 |
Formula | C30H33N5O2 |
CAS No. | 1800340-40-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/ml (121.06 mM), Sonification is recommended
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-986158 1800340-40-2 Chromatin/Epigenetic Epigenetic Reader Domain BMS 986158 BMS986158 inhibit Inhibitor inhibitor